For resectable non-small cell lung cacer with oncogenic driver mutations:current status and future challenges for perioperative treatment strategies
10.3781/j.issn.1000-7431.2024.2401-0051
- VernacularTitle:针对驱动基因突变阳性的可切除非小细胞肺癌:围手术期治疗策略的现状与未来挑战
- Author:
Mingyuan DU
1
;
Yichao HAN
1
;
Hecheng LI
1
Author Information
1. 上海交通大学医学院附属瑞金医院胸外科,上海 200025
- Publication Type:Journal Article
- Keywords:
Resectable non-small cell lung cancer;
Adjuvant therapy;
Oncogenic driver mutations;
Neoadjuvant therapy
- From:
Tumor
2024;44(6):574-589
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the second most common and the deadliest malignant tumor worldwide.With the popularization and improved accuracy of computed tomography(CT)screening technology,more and more patients with lung cancer are detected at an early stage.Concurrently,the rapid development of gene sequencing technology has gradually evolved the treatment model for lung cancer patients into a precision treatment model that integrates pathological classification,staging,and molecular identification.Against this backdrop,targeted drugs such as osimertinib and icotinib have been formally approved for adjuvant therapy after radical resection surgery for resectable non-small cell lung cancer(NSCLC)patients with epidermal growth factor receptor(EGFR)mutations,marking the advent of a new era in adjuvant targeted therapy for lung cancer.Despite this significant progress,the optimal perioperative treatment strategies for resectable NSCLC patients with oncogenic driver mutations(including EGFR mutations)are still unclear.To address this issue,multiple clinical trials are currently ongoing.There is increasing attention on neoadjuvant and adjuvant treatment strategies based on targeted therapy(alone or combined with other treatment).These strategies are expected to provide more precise and effective perioperative treatment options for resectable NSCLC patients with EGFR mutations,thereby further improving their prognosis and quality of life.
